15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 7 firms covering CorMedix Inc, 7 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $13.00 to $22.00, a moderate spread. The average target of $15.71 sits 107% above the current $7.59. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.09 next quarter toward $0.09 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 ratings
Moderate Buy
Strong Buy00%
Buy7100%
Hold00%
Sell00%
Strong Sell00%
Based on 7 analysts giving stock ratings to CorMedix Inc.
As of Jul, 7 of 7 firms rate CRMD a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CRMD EPS & revenue forecast
EPS · NEXT QUARTER
$-0.09
Range $-0.16 – $-0.04 · 5 analysts · -107% YoY
Next period, 5 analysts expect CorMedix Inc to earn $-0.09 a share (range $-0.16 – $-0.04), versus $1.26 a year earlier. Full-year consensus is $0.50, growing to $0.09 the year after.
REVENUE · NEXT QUARTER
$54.0M
Range $53.0M – $55.3M · 5 analysts · -48% YoY
Revenue is expected to reach $54.0M (range $53.0M – $55.3M), -48.2% year-over-year. Full-year consensus is $334.6M, rising to $285.2M next year.
Top analysts covering CorMedix Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CRMD.
#1
Jason Butler
JMP Securities · Rank #22
Buy
$22.00+189.9% to target
Overall win rate
57%
+ Follow
#2
Leonid Timashev
RBC Capital · Rank #69
Buy
$13.00+71.3% to target
Overall win rate
42%
+ Follow
#3
Serge Belanger
Needham · Rank #83
Buy
$15.00+97.6% to target
Overall win rate
48%
+ Follow
#4
Gregory Renza
RBC Capital · Rank #179
Buy
$12.00+58.1% to target
Overall win rate
34%
+ Follow
#5
Jason Kolbert
D. Boral Capital · Rank #346
Buy
$14.00+84.5% to target
Overall win rate
22%
+ Follow
CRMD stock forecast FAQ
What is CRMD's average 12-month price target?+
The 7 analysts with a live target average $15.71 for CorMedix Inc over the next 12 months, ranging from a $22.00 high to a $13.00 low.
Is CRMD stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 7 analyst ratings, 7 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for CRMD?+
The Street-high target is $22.00 (JMP Securities), and the Street-low is $13.00 (RBC Capital). The average of all 7 active targets is $15.71.
How many Wall Street analysts cover CRMD?+
7 analysts have an active rating on CorMedix Inc, and 7 firms carry a live 12-month price target.
Who is the most accurate analyst covering CRMD?+
Among analysts who currently cover CRMD, Jason Butler of JMP Securities has the strongest overall Quantellect track record (Rank #22). Their current call is Buy with a $22.00 target.
What is CorMedix Inc's projected EPS for next quarter?+
The consensus estimate is $-0.09 per share (range $-0.16 – $-0.04) across 5 analysts. Full-year EPS is projected at $0.50, rising to $0.09 the following year.
How much revenue is CorMedix Inc expected to report next quarter?+
Consensus revenue is $54.0M (range $53.0M – $55.3M). Full-year revenue is projected at $334.6M, growing to $285.2M next year.
Have analysts been upgrading or downgrading CRMD lately?+
As of Jul, 7 of 7 firms rate CRMD a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CRMD calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
